Zevra Therapeutics, Inc. Stock Prediction and Forecast [ZVRA]

AI-generated source summary

The analysis suggests ZVRA is a buy candidate. The system has ranked Zevra Therapeutics as a buy candidate with a score of 3.492. Those who adhered to the analysis would have experienced a gain of approximately 50.96% since the initial recommendation 66 days prior, with an average daily gain of 0.77%. The stock is within a broad and strong upward trend, the current three month trend indicates a potential change of 43.34% over the upcoming three months with a possible return ranging from 32.66% to 72.75%. Analysts assign ZVRA a strong sell rating. Our stop loss is set at $11.29, 4% from current, with medium risk as we approach the third quarter, further regulatory developments may affect EMA approval, and favorable reimbursement dynamics are expected to be a key to upside, regulatory setbacks, or commercial hurdles, will constrain valuation.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   13 Aug 2025, 03:19 UTC

   The analyst published the original source item.

2. First prediction resolved

   13 Aug 2025, 13:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   13 Aug 2025, 13:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:47 UTC

   1 eligible signal linked to this case.

6. Outcome tracking started

   02 Jul 2026, 02:15 UTC

   Tahlil Plus began monitoring the extracted predictions.